Headlands Technologies LLC Purchases 9,220 Shares of Illumina, Inc. (NASDAQ:ILMN)

Headlands Technologies LLC increased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 714.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,511 shares of the life sciences company's stock after buying an additional 9,220 shares during the quarter. Headlands Technologies LLC's holdings in Illumina were worth $1,464,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Vanguard Group Inc. boosted its position in Illumina by 15.0% during the third quarter. Vanguard Group Inc. now owns 17,967,758 shares of the life sciences company's stock valued at $2,466,614,000 after purchasing an additional 2,336,935 shares during the last quarter. Barclays PLC boosted its position in Illumina by 120.0% during the third quarter. Barclays PLC now owns 1,768,355 shares of the life sciences company's stock valued at $242,758,000 after purchasing an additional 964,709 shares during the last quarter. abrdn plc boosted its position in Illumina by 764.9% during the fourth quarter. abrdn plc now owns 339,023 shares of the life sciences company's stock valued at $47,206,000 after purchasing an additional 299,827 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in Illumina by 245.7% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 417,876 shares of the life sciences company's stock valued at $57,366,000 after purchasing an additional 296,990 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its position in Illumina by 6.6% during the third quarter. Bank of New York Mellon Corp now owns 3,648,935 shares of the life sciences company's stock valued at $500,926,000 after purchasing an additional 225,074 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on ILMN shares. Barclays boosted their price target on Illumina from $85.00 to $100.00 and gave the stock an "underweight" rating in a research report on Wednesday, April 10th. TD Cowen cut Illumina from an "outperform" rating to a "market perform" rating and set a $144.00 price target for the company. in a research report on Thursday, January 4th. HSBC cut Illumina from a "buy" rating to a "hold" rating in a research report on Tuesday, January 16th. OTR Global reissued a "mixed" rating on shares of Illumina in a research report on Wednesday, March 20th. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $253.00 price objective on shares of Illumina in a research report on Tuesday, April 9th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $167.70.

Illumina Price Performance

NASDAQ ILMN traded up $1.23 during trading hours on Friday, reaching $122.28. 829,331 shares of the company's stock were exchanged, compared to its average volume of 1,470,247. The stock has a market cap of $19.47 billion, a PE ratio of -16.66 and a beta of 1.19. Illumina, Inc. has a one year low of $89.00 and a one year high of $213.91. The firm has a fifty day moving average of $131.51 and a 200-day moving average of $127.24. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.26.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings data on Thursday, February 8th. The life sciences company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.13. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. The firm had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter in the prior year, the business earned $0.14 EPS. The business's revenue for the quarter was up 3.6% compared to the same quarter last year. On average, equities research analysts predict that Illumina, Inc. will post 0.91 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Jacob Thaysen purchased 7,330 shares of the business's stock in a transaction dated Thursday, February 22nd. The shares were bought at an average price of $135.29 per share, with a total value of $991,675.70. Following the purchase, the chief executive officer now directly owns 14,861 shares in the company, valued at approximately $2,010,544.69. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.17% of the stock is currently owned by company insiders.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.